Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: J Inorg Biochem. 2016 Jul 27;165:170–180. doi: 10.1016/j.jinorgbio.2016.07.016

Figure 3. Evaluation of P3A1-MWCNT[1] uptake and drug release in cancer cells.

Figure 3

(A) MDA-MB-231 cells were treated with P3A1-MWCNT[1] (20 µg/mL MWCNT) for 16 hours, fixed with glutaraldehyde, and prepared for TEM. Images of P3A1-MWCNT[1] (white arrows) internalized by breast cancer cells are shown. Numbered regions in the lower magnification image (30,000x; scale bar = 500 nm) are shown in higher magnification (90,000x; scale bar =100 nm) in the adjacent images. (B) MDA-MB-231 cells were treated with vehicle, drug-free DSPE-mPEG coated MWCNT, P3A1-MWCNT[1] or P3A1 (7.5 µM P3A1 or 9.8 µg/mL MWCNT) for 6 h, and then assessed for P3A1 fluorescence by confocal microscopy. (C) MDA-MB-231 cells were treated with vehicle, P3A1-MWCNT[1] or P3A1 (1.0 µM) for 6 h, harvested, microwave-assisted digested, analyzed by ICP-MS, and cell-associated platinum content is shown.